Skip to Main Content

Bridget Keenan


Medical oncologist
Cancer researcher and outdoor enthusiast

About me

Pronouns: She | Her | Hers

Dr. Bridget Keenan is an oncologist and physician-scientist, a doctor particularly focused on research. She cares for patients with solid organ tumors who are seeking or enrolled in immunotherapy clinical trials (studies of promising new treatments). She has a special interest in digestive system cancers.

Keenan's research investigates various immunotherapy approaches to fighting cancer, including checkpoint inhibitors (drugs that prevent an immune system response that may otherwise allow cancer cells to evade destruction), cellular therapies, bispecific antibodies (parts of lab-produced antibodies that bind to T cells and tumors so that cancer cells are directly targeted) and other new treatments.

Keenan earned her medical degree and a doctorate in immunology at the Johns Hopkins University School of Medicine. At UCSF, she completed a residency in internal medicine and a fellowship in hematology and oncology.

  • Education

    Johns Hopkins School of Medicine, MD, 2015

    John Hopkins School of Medicine, PhD, Immunology, 2015

  • Residencies

    UCSF, Internal Medicine, 2017

  • Fellowships

    UCSF, Hematology-Oncology, 2021

  • Academic Title

    Assistant Professor

I help patients with cancer learn whether an immunotherapy clinical trial is right for them and research better treatments using the immune system.

Where I see patients (1)

    Decorative Caduceus

    A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can...


    Decorative Caduceus

    A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin...

    To evaluate the safety of ATG-101. It is the responsibility of the investigator to record and document all AEs (occurring from the first dose of study treatment on C1D1) throughout the study. Clinically significant symptoms and si...